First Trust Advisors
FATE icon

First Trust Advisors’s Fate Therapeutics FATE Stock Holding History

First Trust Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,837
Closed -$420K – 2523
2022
Q1 		$420K Buy
+10,837
New +$420K ﹤0.01% 2298
2021
Q4 		– Sell
-45,618
Closed -$2.7M – 2534
2021
Q3 		$2.7M Sell
45,618
-13,925
-23% -$1.09M ﹤0.01% 1650
2021
Q2 		$5.17M Sell
59,543
-13,665
-19% -$1.1M 0.01% 1339
2021
Q1 		$6.04M Sell
73,208
-35,117
-32% -$3.36M 0.01% 1135
2020
Q4 		$9.85M Buy
108,325
+41,427
+62% +$2.57M 0.01% 836
2020
Q3 		$2.67M Sell
66,898
-13,881
-17% -$485K ﹤0.01% 1227
2020
Q2 		$2.77M Sell
80,779
-20,357
-20% -$607K ﹤0.01% 1218
2020
Q1 		$2.25M Buy
101,136
+80,566
+392% +$2.04M 0.01% 1216
2019
Q4 		$403K Sell
20,570
-164,130
-89% -$2.61M ﹤0.01% 2187
2019
Q3 		$2.87M Buy
184,700
+50,312
+37% +$964K 0.01% 1327
2019
Q2 		$2.73M Buy
+134,388
New +$2.42M 0.01% 1388

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

First Trust Advisors's FATE Position: Q2 2022 in Review

First Trust Advisors sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 10,837 shares — an estimated $420K sold.

First Trust Advisors first reported a position in FATE in Q2 2019 and held it in 11 quarters. The position peaked at $9.85M in Q4 2020. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • First Trust Advisors reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • First Trust Advisors sold 10,837 Fate Therapeutics shares in Q2 2022, an estimated $420K.
  • First Trust Advisors first reported a position in Fate Therapeutics in Q2 2019 and held it in 11 quarters.
  • First Trust Advisors's Fate Therapeutics position peaked at $9.85M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on First Trust Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.